4 citations
,
December 2020 Methotrexate may help stabilize frontal fibrosing alopecia.
November 2023 in “SKIN The Journal of Cutaneous Medicine” May 2025 in “Journal of the European Academy of Dermatology and Venereology” Etrasimod is safe but not effective for severe alopecia areata, though it may help milder cases.
13 citations
,
January 2017 in “Chemical & Pharmaceutical Bulletin” Certain compounds, especially those with a propionic substituent, could potentially be new treatments for hair loss and similar disorders.
July 2024 in “Forum Dermatologicum” 13 citations
,
February 2025 in “Journal of the European Academy of Dermatology and Venereology” Ritlecitinib shows promise for treating alopecia areata, especially with early and extended treatment.
November 2024 in “SKIN The Journal of Cutaneous Medicine” Ritlecitinib effectively reduces severe hair loss in alopecia areata over 24 months.
March 2026 in “Journal of Translational Autoimmunity” Ruxolitinib helps regrow hair in alopecia areata by blocking inflammation, reducing stress, and controlling cell death.
18 citations
,
November 2012 in “Current opinion in urology” Finasteride and dutasteride are equally effective and safe for treating benign prostatic hyperplasia.
April 2023 in “Journal of Investigative Dermatology” Two new IRAK4-inhibitors effectively reduced skin inflammation and immune response markers in healthy volunteers.
6 citations
,
February 2020 in “Journal of Natural Products” A new compound from a sponge strongly inhibits an enzyme linked to male-pattern hair loss without being toxic at low levels.
November 2025 in “Journal of Investigative Dermatology” Combining MMP-9 and JAK inhibitors can effectively prevent skin depigmentation in vitiligo.
1 citations
,
May 2015 in “Journal of The American Academy of Dermatology” Finasteride for hair loss in young men may significantly increase the risk of sexual dysfunction.
November 2025 in “SKIN The Journal of Cutaneous Medicine” Ritlecitinib is generally safe for adolescents with alopecia areata over 5 years.
36 citations
,
June 2014 in “International Journal of Dermatology” Dutasteride helps hair growth in those unresponsive to finasteride, but may cause more sexual dysfunction.
January 2024 in “Case Reports in Endocrinology” Cortisone tapering may help improve severe myasthenia gravis and alopecia areata after thymectomy.
1 citations
,
January 2023 in “SAGE open medical case reports” A new treatment called deucravacitinib helped a patient with severe hair loss grow their hair back quickly.
379 citations
,
May 2016 in “Cochrane library” Corticosteroids, especially prednisone, improve short-term muscle strength in Duchenne muscular dystrophy but have manageable side effects.
3 citations
,
April 2022 in “Neuroscience Letters” Finasteride may help treat autism by reducing inflammation and oxidative stress.
May 2025 in “Reactions Weekly”
1 citations
,
November 2023 in “Indian Journal of Science and Technology” Eclipta alba may improve memory and help treat Alzheimer's disease.
January 2024 in “Pharmaceutical journal/The pharmaceutical journal” Ritlecitinib can help about 14,000 people with severe hair loss.
October 2022 in “Rheumatology (Bulgaria)” Accurate diagnosis of progressive supranuclear palsy requires thorough neurological assessments and MRI.
25 citations
,
June 2017 in “Scientific reports” Stress worsens Tourette symptoms by increasing allopregnanolone levels.
May 2023 in “Reactions Weekly” January 2013 in “Reactions Weekly”
October 2011 in “Reactions Weekly” A man had a severe allergic reaction to sulfasalazine, with symptoms improving after treatment and follow-up.
47 citations
,
June 2011 in “Movement Disorders” The LRRK2-G2019S mutation in Parkinson's disease has a lifetime penetrance of 25-35%, and finasteride may help reduce symptoms in adult male Tourette syndrome patients.
1 citations
,
June 2015 in “Journal of anatomy” A compound named ZCZ90 can increase muscle spindle firing, potentially helping treat muscle spasms and hypertension.
1 citations
,
August 2021 in “Journal of Investigative Dermatology” ASLAN004 was safe and well-tolerated, supporting further development for treating certain diseases.